FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.
You may also be interested in...
FDA Pressed To Clarify Permissible Formulary, Clinical Guideline Communications
Citizen petition from seven firms asks agency to issue regulations related to four areas of off-label communications.
FDA Pressed To Clarify Permissible Formulary, Clinical Guideline Communications
Citizen petition from seven firms asks agency to issue regulations related to four areas of off-label communications.
Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ
Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.